- Home
- KYNB vs CUE Comparison
KYNB vs CUE Comparison
Compare KYNB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | CUE |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 27.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | KYNB | CUE |
|---|---|---|
| Price | $6.82 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 36.8K | ★ 326.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $6.72 | $0.23 |
| 52 Week High | $9.58 | $1.12 |
Technical Indicators
Market Signals| Indicator | KYNB | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 46.74 |
| Support Level | N/A | $0.29 |
| Resistance Level | $8.89 | $0.36 |
| Average True Range (ATR) | 0.48 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 9.05 | 78.78 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.